Research Grants Program Office (RGPO)
Celecoxib in breast cancer prevention and therapy.
- Author(s): Li, Jieqing
- Hao, Qiongyu
- Cao, Wei
- Vadgama, Jaydutt V
- Wu, Yong
- et al.
Published Web Locationhttps://doi.org/10.2147/cmar.s178567
Breast cancer has a high incidence worldwide. The results of substantial studis reveal that inflammation plays an important role in the initiation, development, and aggressiveness of many malignancies. The use of celecoxib, a novel NSAID, is repetitively associated with the reduced risk of the occurrence and progression of a number of types of cancer, particularly breast cancer. This observation is also substantiated by various meta-analyses. Clinical trials have been implemented on integration treatment of celecoxib and shown encouraging results. Celecoxib could be treated as a potential candidate for antitumor agent. There are, nonetheless, some unaddressed questions concerning the precise mechanism underlying the anticancer effect of celecoxib as well as its activity against different types of cancer. In this review, we discuss different mechanisms of anticancer effect of celecoxib as well as preclinical/clinical results signifying this beneficial effect.